Research Grade Monalizumab 研究级别药物对照抗体
一、中文名称：莫那利珠单抗
二、产品描述：Monalizumab (IPH2201) 是一种靶向自然杀伤细胞群 2A (NKG2A) 的免疫检查点抑制剂。Monalizumab 是一种人源化抗 NKG2A 的单克隆抗体，可增加 IFN-γ 产生，从而促进自然杀伤细胞功能。Monalizumab 可用于头颈部鳞状细胞癌 (HNSCC) 的研究。
三、产品详情：
货号：DHD71901
表达系统：Mammalian Cells
种属反应性：Human
宿主：Humanized
同种型：IgG4 - kappa
克隆类型：Monoclonal
靶标：KLRC1, NKG2 - A/NKG2 - B type II integral membrane protein, NKG2 - A/B - activating NK receptor, CD159 antigen - like family member A, CD159a, NK cell receptor A, NKG2A
浓度：6.65 mg/ml
内毒素水平：Please contact with the lab for this information.
纯度：>95% as determined by SDS - PAGE.
纯化方式：Protein A/G purified from cell culture supernatant.
Accession 号：P26715
克隆号：Monalizumab
应用：Research Grade Biosimilar
状态：Liquid
保存溶液：0.01M PBS, pH 7.4.
稳定性和存储：Use a manual defrost freezer and avoid repeated freeze - thaw cycles. Store at 4°C short term (1 - 2 weeks). Store at -20°C 12 months. Store at -80°C long term.
别名：IPH - 2201, NN - 8765, NNC - 0141 - 0000 - 0100, NNC - 141 - 01000, monolizumab, anti - NKG2A, humZ270, CAS: 1228763 - 95 - 8
四、参考文献：
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. PMID: 31308062
Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. PMID: 37782273
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. PMID: 40450142
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. PMID: 35452273
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. PMID: 34638090
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. PMID: 40300079
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM). PMID: 40311183
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.biolabreagent.com/
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
